Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Bioprinting & 3D-Printing in the Life Sciences EU 2018

Itedale Namro Redwan's Biography



Itedale Namro Redwan, Senior Principal Scientist/Team Leader, CELLINK

Itedale holds a PhD degree in Chemistry with emphasis on Medicinal/Organic Chemistry from the University of Gothenburg. She obtained her Postdoctoral training in Chemical Biology at the Gladstone Institutes in San Francisco. She was an Assistant Professor at the Clinical Chemistry and Transfusion Medicine at the University of Gotehnburg prior to joining CELLINK as a Senior Principal Scientist/Scientific Officer. Itedale is cuttently leading the Bioink and Tissue Engineering R&D team.

Itedale Namro Redwan Image

3D Bioprinting of Human Hepatic Tissue Models

Thursday, 7 June 2018 at 16:00

Add to Calendar ▼2018-06-07 16:00:002018-06-07 17:00:00Europe/London3D Bioprinting of Human Hepatic Tissue ModelsBioprinting and 3D-Printing in the Life Sciences EU 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

In this study, we evaluate the bioprintability of human liver ECM under physiological conditions to assess the in vitro biocompatibility with human hepatic cells and to model liver fibrosis in vitro. Human hepatic cell lines (HepG2 and LX2) were gently mixed with HEP X™ bioink using a CELLMIXER® directly into a cartridge before bioprinting. Tissue printing was performed in a BIO X 3D printer under physiological conditions. Bioprinted tissues were maintained in 3D culture up to 14 days and exposed to TGFß1 for 6 days in order to promote an in vitro fibrogenic process. The resultant bioprinted liver tissue was analysed by viability assay, histology and gene and protein expression. The combination of human liver ECM bioink with liver cell types resulted in an increased cell viability and proliferation compared to control bioink. Pro-fibrogenic genes and proteins including aSMA (p<0.001) and pro-COL1 (p<0.001) were up-regulated in the LX2-laden constructs after 6 days of TGFß1 exposure. HepG2-laden constructs showed spontaneous formation of spheroids after 14 days in culture with up-regulation of albumin gene expression and protein secretion after 14 days compared to 7 days (p<0.001). This is the first report describing the bioprinting of human hepatic tissue using human liver ECM as bioink. This is a key advance in the development of cell-instructive bioinks for the study of liver disease and for the development of 3D hepatic tissue for transplantation.


Add to Calendar ▼2018-06-07 00:00:002018-06-08 00:00:00Europe/LondonBioprinting and 3D-Printing in the Life Sciences EU 2018Bioprinting and 3D-Printing in the Life Sciences EU 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com